Targeted therapies in the treatment of advanced/metastatic NSCLC

A.G. Pallis, L. Serfass, R. Dziadziusko, J.P. Van Meerbeeck, Dean Fennell, D. Lacombe, J. Welch, C. Gridelli

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)


The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially during the last years. Chemotherapy remains the cornerstone of treatment and prolongs survival with a positive impact on quality of life. However, we seem to have reached a plateau of activity in the treatment of NSCLC. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets has improved the outcome in selected patients with advanced NSCLC. Furthermore, the use of erlotinib and gefitinib is an alternative for second line treatment. Advances in our understanding of molecular biology of cancer and mechanisms of tumourigenesis have further enabled the discovery of several potential molecular targets and development of novel 'targeted therapies'. The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC. (C) 2009 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)2473-2487
Number of pages15
JournalEuropean Journal of Cancer
Issue number14
Publication statusPublished - Sept 2009

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Targeted therapies in the treatment of advanced/metastatic NSCLC'. Together they form a unique fingerprint.

Cite this